Bipartisan members of Congress sent a letter requesting that the Drug Enforcement Administration (DEA) allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.
Optimi Health Corp. has announced a second provisional patent for a proprietary two-part processing method that involves the extraction and transdermal delivery of psilocybin active components.
Luke Goldstein at The American Prospect explores the commercialization of psilocybin mushroom as part of their Rollups series.
Jennifer Mithcell at Scientific America explores how MDMA is being used to treat PTSD.
Psygen Industries Ltd. is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., received a dealer’s licence issued by Health Canada on January 17, 2022. Upon completion of its facility in Calgary, Psygen will begin onsite manufacturing of synthetic psychedelics in accordance with Good Manufacturing Practices (GMP) for use in clinical and scientific research.
Numinus Wellness Inc. has announced that it has completed key steps to prepare to enrol participants at its clinics participating in “A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)”, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS).
Awakn Life Sciences Corp. has announced that it has signed a Memorandum of Understanding with the Multidisciplinary Association for Psychedelic Studies (MAPS) to explore a partnership to utilize MDMA-assisted therapy to treat Alcohol Use Disorder (AUD) in Europe.
COMPASS Pathways has announced the findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD).
Eleusis is going public through a merger with a blank-check firm, according to people with knowledge of the matter. The U.K.-based company will combine with Silver Spike Acquisition Corp. II in a deal that values Eleusis at about $450 million.
Mind Medicine (MindMed) Inc has announced that it has enrolled the first subjects into its Session Monitoring System (SMS-01) study evaluating the passive collection of sensory data during a consciousness-altering therapeutic session. SMS-01 utilizes MindMed’s Session Monitoring System (MSMS), which it believes could have therapeutic applications in the treatment of psychiatric disorders.
Mydecine Innovations Group has announced it has signed a Letter of Intent (LOI) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada, to collaborate on expanding psychedelic-assisted psychotherapy to patients.
Numinus Wellness has announced the submission of the clinical trial application (CTA) to Health Canada to commence the Phase I clinical trial of a naturally derived Psilocybe extract formulation, NBIO-01, for psychedelic-assisted therapies.
Wesana Health has announced that the U.S Food and Drug Administration (U.S. FDA) granted the Company’s request for a pre-IND (Investigational New Drug) meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder (MDD).
Cybin Inc. has announced that an Institutional Review Board has approved a Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
PharmaTher has announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug (“IND”) application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Lateral Sclerosis (“ALS”), also known as Lou Gehrig’s disease. The Study will be conducted at the University of ...
Field Trip Health has announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Field Trip’s patent application No. 17/364,047 for claims related to FT-104 (informally known as “Isoprocin Glutarate”), Field Trip’s first novel psychedelic molecule in development. Claims in the allowed patent application titled, “Tryptamine Prodrugs”, cover composition ...
atai Life Sciences have announced that the U.S. Food and Drug Administration (FDA) has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the study early this year through its platform company Perception Neuroscience.
A new archaeological study adds to the rich history of psychedelics in South America. Archaeologists found vilca seeds at a site in Southern Peru which they believe were added beer at feasts to help Wari leaders, who ruled in Peru over 1,400 years ago, reinforce their power and build a sense of community.
National Institute on Drug Abuse (NIDA) Director Nora Volkow says the “train has left the station” on psychedelics. In light of the recent workshop on psychedelics hosted by the NIH, Ms. Volkow stated that people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn ...
Researchers at the University of Syndey have been awarded over $2.2M to study MDMA-assisted therapy to treat combined post-traumatic stress disorder (PTSD) and alcohol use disorder, as well as a clinical trial of psilocybin-assisted psychotherapy in anorexia nervosa.
The hosts of the Business Trip podcast have started a $25M fund with Dina Burkitbayeva to invest in psychedelic medicine companies and mental health technologies: PsyMed Ventures.
An amendment to federal regulations will allow physicians in Canada to request access to drugs like psilocybin and MDMA through the Special Access Program. A major win for the therapeutic potential of psychedelics.
A new bill introduced by lawmakers in Washington State would establish a legal, regulated psilocybin industry available to all adults 21 years and older regardless of mental health status.
Psychedelic reporter Shayla Love explores the implications of a recent publication on the crystalline structures of psilocybin has for patents within the psychedelic industry.
Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.
Tryp Therapeutics announced today the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company’s ability to proceed with a Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder.
Cybin (CYBN) was recently awarded a Notice of Allowance for it CYB004 deuterated psychedelic tryptamine used to treat anxiety disorders.
Entheon Biomedical Corp. announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc., is now available for sale in Canada and the United States.
Mydecine Innovations Group, a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today that the Company has signed an LOI with Maya.
Mind Medicine (MindMed) Inc. today announced that the U.S. Food and Drug Administration has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide (LSD) for the treatment of generalized anxiety disorder (GAD).
Find Psychedelic News Articles
Discover the latest news articles published on psychedelics with a focus on psychedelics as medicine. We cover all popular press, press releases, notable articles, and blogs on psychedelics.
Read the full articles on the individual websites, press releases on Blossom, and our quick take directly in the summary.
